Renaissance Technologies’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Renaissance Technologies’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-81,688	Closed	-$302K	–	3735
2017 Q4	$302K	Buy	81,688 +17,900	+28%	+$73.3K	﹤0.01%	3023
2017 Q3	$261K	Sell	63,788 -5,800	-8%	-$22.2K	﹤0.01%	2937
2017 Q2	$259K	Buy	69,588 +51,600	+287%	+$205K	﹤0.01%	2940
2017 Q1	$74K	Buy	+17,988	New	+$75.6K	﹤0.01%	3113
2015 Q4	–	Sell	-56,633	Closed	-$931K	–	3536
2015 Q3	$931K	Sell	56,633 -22,399	-28%	-$459K	﹤0.01%	2418
2015 Q2	$1.77M	Sell	79,032 -23,331	-23%	-$369K	﹤0.01%	2142
2015 Q1	$1M	Buy	+102,363	New	+$1M	﹤0.01%	2309
2014 Q1	–	Sell	-26,117	Closed	-$276K	–	3131
2013 Q4	$276K	Sell	26,117 -91,777	-78%	-$1.03M	﹤0.01%	2528
2013 Q3	$1.46M	Buy	117,894 +35,211	+43%	+$371K	﹤0.01%	1820
2013 Q2	$779K	Buy	+82,683	New	+$1.06M	﹤0.01%	2049

Renaissance Technologies's CASC Position: Q1 2018 in Review

Renaissance Technologies sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 81,688 shares — an estimated $302K sold.

Renaissance Technologies first reported a position in CASC in Q2 2013 and held it in 10 quarters. The position peaked at $1.77M in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

Renaissance Technologies reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Renaissance Technologies sold 81,688 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $302K.
Renaissance Technologies first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 10 quarters.
Renaissance Technologies's Cascadian Therapeutics, Inc. position peaked at $1.77M in Q2 2015.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Renaissance Technologies's 13F filing for Q1 2018, filed 14 May 2018.